|
|
Article: SHIRE PLC - FDA Approves VYVANSE to Treat ADHD in Adults.
- Article from:
- PR Newswire UK Disclose
- Article date:
- April 23, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FDA Approves VYVANSEacents (lisdexamfetamine dimesylate), the First and Only
Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Within the first eight months since its introduction in the United States,
VYVANSE has achieved over one million prescriptions
In a clinical study with adults, VYVANSE was shown to significantly improve the
symptoms of ADHD (inattention, hyperactivity and impulsivity)1
Basingstoke, U.K. and Philadelphia, PA - April 23, 2008- Shire plc (LSE: SHP,
NASDAQ: SHPGY,), the global specialty biopharmaceutical company, today
announced that it has received approval from the U.S. Food and Drug
Administration ...